DNA Test Report - MedGenome Laboratories

Patient Details

Clinical Diagnosis / Symptoms / History

• Gallbladder stone on USG abdomen
• Low faecal elastase levels

Key Finding

VARIANT OF UNCERTAIN SIGNIFICANCE RELATED TO THE GIVEN PHENOTYPE WAS DETECTED

Variant Interpretation

• A heterozygous missense variant was found in exon 7 of the CTRC gene (chr1:g.15445660G>A; Depth: 162x).
• This results in an amino acid change: Isoleucine substituted for Valine at codon 235 (p.Val235Ile).
• This variant has been previously reported in patients with pancreatitis, and functional studies show it causes slightly diminished enzyme activity (ref [17]: Rosendahl et al., 2008).
• The variant has conflicting interpretations of pathogenicity in the ClinVar database.
• Minor allele frequencies: 0.1% (1000 Genomes), 0.04% (gnomAD), 0.4% (internal Indian population database).
• In silico predictions: Probably damaging (PolyPhen-2/HumDiv), Damaging (SIFT, LRT, MutationTaster2).
• The reference codon is conserved across species.

Recommendations

1. Parental/family sequencing is recommended to assess variant segregation and confirm significance.
2. Genetic counselling is advised.
3. If results do not match clinical findings, additional testing should be considered as per the referring clinician.

Sequencing Quality Metrics

Summary

Recent Research: CTRC Variants and Pancreatitis

1. Mechanism - How CTRC Protects the Pancreas

2. The p.Val235Ile Variant - Directly Relevant to This Report

• It is classified as a moderate-to-low risk variant, retaining 36-55% of wild-type CTRC activity (compared to high-risk variants like p.Ala73Thr which have <10% residual activity).
• The 2022 meta-analysis (Takáts et al., PLoS One) found p.Val235Ile (also written p.V235I) to have an odds ratio (OR) of 4.5 (95% CI 2.2-9.1) for chronic pancreatitis - meaning heterozygous carriers have approximately a 4.5-fold increased risk of CP compared to non-carriers. [PMID: 35594281]
• Overall, heterozygous loss-of-function CTRC variants increase CP risk approximately 3-7-fold.

3. Meta-Analyses (Highest-Level Evidence)

• Analyzed 4 clinically common CTRC variants across published studies.
• p.V235I OR = 4.5 (CI 2.2-9.1) for chronic pancreatitis.
• Homozygosity or compound heterozygosity carries higher risk than simple heterozygosity.
• Conclusion: confirms the clinical significance of CTRC variants and justifies routine genetic screening in CP patients.

• Focused on the common synonymous variant c.180C>T (p.Gly60=), which is present in ~30% of CP cases.
• Found it increases CP risk ~2-fold (heterozygous) and ~5-fold (homozygous), potentially through reducing CTRC mRNA levels.
• This variant can co-occur with p.Val235Ile (they are sometimes found on the same haplotype), compounding risk.

4. Pediatric CTRC - Directly Relevant for an 11-Year-Old

• Real-world genetic testing of pediatric CP cases - the closest demographic match to Yagay.
• Identified 5 novel heterozygous CTRC variants in 5 children with CP.
• Key finding: 3 out of 5 novel variants proved benign on functional analysis, underlining that variant classification without functional data can be misleading.
• Underscores why the VUS classification in Yagay's report is appropriate - functional analysis is "indispensable for reliable determination of pathogenicity."

5. CTRC and Cancer Risk

• Large study (4,528 PDAC cases, 52,659 controls) examined germline variants in all 11 CP-associated genes including CTRC.
• CTRC was not significantly associated with pancreatic ductal adenocarcinoma (PDAC) risk in this study - the main cancer-risk signals were from PRSS1 and CFTR.
• Reassuring that the CTRC p.Val235Ile finding in Yagay does not appear to carry a major cancer-predisposition signal.

6. Current Consensus on Variant Classification

• Functional data (enzyme activity assays)
• Population frequency
• Segregation in families
• In silico predictions

Summary Table

Clinical Implications for Yagay's Case

1. The p.Val235Ile finding is clinically meaningful - an OR of ~4.5 for CP is substantial, even at VUS classification.
2. The parental testing recommendation in the MedGenome report aligns perfectly with current evidence - if one parent is an asymptomatic carrier, this shifts interpretation toward a susceptibility variant; if the variant arose de novo or both parents are symptomatic carriers, it strengthens the disease link.
3. Given that Yagay already has recurrent acute pancreatitis at age 11, the genetic finding provides biological plausibility even without reclassification.
4. No PRSS1 pathogenic variant was detected, which is notable since PRSS1 carries the strongest hereditary pancreatitis signal and the highest cancer risk - its absence is clinically reassuring.

Advances in Hereditary/Genetic Pancreatitis: Research & Treatment Progress

Current State: Why Treatment Remains Difficult

A. Current Standard Management (2025 Guidelines)

1. Pain control - analgesic ladder; avoid opioids where possible
2. Fluid resuscitation - goal-directed, lactated Ringer's preferred
3. Early enteral nutrition - oral/nasogastric feeding within 24-48 hours
4. Enzyme replacement therapy (PERT) - for exocrine pancreatic insufficiency (low faecal elastase, as seen in Yagay's presentation)
5. Avoidance of triggers - alcohol, high-fat diet, smoking
6. Gallstone management - Yagay has a gallbladder stone; cholecystectomy is recommended to prevent further attacks
7. Prevention of recurrence - the guidelines specifically call for future research into targeted therapies for systemic inflammation and organ dysfunction

B. Endoscopic Interventions in Children (Growing Field)

• ERCP (Endoscopic Retrograde Cholangiopancreatography) is increasingly used in children with recurrent pancreatitis to relieve pancreatic duct obstruction, manage strictures, and treat ductal stones.
• Endoscopic ultrasound (EUS)-guided therapies and single-operator pancreatoscopy are expanding indications in pediatric centers.
• Technical success and adverse event rates in children are now comparable to adults, though access to pediatric-trained endoscopists remains a challenge.
• This is relevant for Yagay - if ductal dilation or stricture is found on further imaging, endoscopic decompression could reduce recurrence frequency.

C. The Camostat (Oral Trypsin Inhibitor) Trial - A Setback

• Camostat is an oral serine protease inhibitor (used for decades in Japan) that theoretically inhibits trypsin-driven pancreatic autodigestion.
• This was the highest-quality RCT to date: 264 adults with painful CP randomized to camostat 100/200/300 mg TDS vs placebo.
• Result: Camostat did NOT outperform placebo on pain reduction at any dose.
• Conclusion: Pain in chronic pancreatitis is multifactorial (neural, structural, inflammatory), so blocking trypsin alone is insufficient. The study called for better mechanistic understanding before future trials.
• This rules out camostat as a standalone therapy for pain, though the trypsin-inhibition rationale is still being explored in other forms.

D. Gene Therapy - The Most Exciting Horizon

1. Gene Augmentation (for Loss-of-Function Variants like CTRC p.Val235Ile)

• The goal is to restore missing protective gene function.
• AAV8-hSPINK1: An adeno-associated virus vector delivering the SPINK1 gene (a trypsin inhibitor) into the pancreas has been validated in mouse models of pancreatitis by Wang et al. (2024). It significantly reduced pancreatitis severity, fibrosis, apoptosis, and autophagy.
• Similar logic applies to CTRC: delivering functional CTRC to restore trypsinogen degradation. This is in pre-clinical development.
• Key challenge: the pancreas is a difficult organ to transduce efficiently with AAV vectors - developing pancreatic-tropic delivery systems is an active research priority.

2. Gene Inhibition / RNA Silencing (for Gain-of-Function Variants like PRSS1)

• For PRSS1 gain-of-function mutations, antisense oligonucleotides (ASOs) or siRNA to silence mutant trypsinogen expression are being studied.
• Analogous to ASO therapies already FDA-approved for other conditions (e.g., spinal muscular atrophy, hereditary transthyretin amyloidosis).

3. Gene Editing (CRISPR-Cas9)

• Precise correction of the causative variant at the DNA level.
• Demonstrated in cell and animal models; not yet in pancreatic disease clinical trials.
• The pancreas presents specific challenges: limited accessibility for direct delivery, risk of off-target editing in a secretory-enzyme-rich organ.

4. Lipid Metabolism Pathway Therapies (Already Approved)

• For pancreatitis driven by hypertriglyceridemia (a separate pathway), several gene medicines are already approved:
  • Alipogene tiparvovec (gene therapy for LPL deficiency)
  • Volanesorsen and Olezarsen (antisense oligonucleotides targeting ApoC-III)
  • ARO-APOC3 (RNAi therapy)
• These reduce triglyceride-driven acute pancreatitis risk. Not directly relevant to Yagay's CTRC case, but proof that gene-based pancreatitis therapies can reach the clinic.

E. Surgical Option - Total Pancreatectomy with Islet Auto-Transplantation (TP-IAT)

• For severe hereditary pancreatitis unresponsive to medical/endoscopic therapy, total pancreatectomy combined with islet auto-transplantation (TP-IAT) is the surgical option of last resort.
• The patient's own islet cells are harvested from the removed pancreas and infused into the portal vein, reducing the risk of post-surgical diabetes.
• 10-year Australian experience shows meaningful pain relief and preservation of insulin secretion in a subset of patients.
• In children with hereditary pancreatitis this is well-established in specialist centers (particularly in the US and Europe), offering a potential long-term cure of symptoms.
• Timing matters: earlier surgery (before extensive fibrosis) yields better islet yields and lower rates of post-operative diabetes.

F. Nutritional & Exocrine Management

• Pancreatic Enzyme Replacement Therapy (PERT): lipase + protease + amylase with every meal and snack.
• Fat-soluble vitamin monitoring: vitamins A, D, E, K can become deficient.
• Low-fat diet guidance to reduce pancreatic stimulation.
• Nutritional surveillance is particularly important in a growing child.

Summary: Treatment Roadmap for Yagay's Condition

Total Pancreatectomy with Islet Autotransplantation (TP-IAT)

What It Is

1. Total pancreatectomy - the entire pancreas is surgically removed, eliminating the source of recurrent inflammation and pain.
2. Islet autotransplantation - within hours of removal, the patient's own insulin-producing islet cells are extracted from the excised pancreas, purified, and infused through a catheter into the portal vein, where they engraft in the liver and resume insulin secretion.

Who It Is For - Indications

• Intractable chronic or recurrent acute pancreatitis with debilitating pain
• Failed adequate trials of medical therapy (analgesics, enzyme replacement, dietary changes)
• Failed or unsuitable for endoscopic therapy (ERCP, ductal decompression)
• Failed or unsuitable for lesser surgical procedures
• No prior type 1 diabetes (islet cells must be functional before surgery)
• No pancreatic malignancy
• Fit for major abdominal surgery
• Able to manage complex post-operative care

The Best Current Evidence

• Prospective multicenter study across 12 US centers
• 384 participants; mean age 30 years; 34% were pediatric (like Yagay)
• 62% female; all had intractably painful CP or recurrent acute pancreatitis (RAP)

• Daily abdominal pain dropped from 65% → 23% of patients
• Mean pain score fell from 4.9 → 2.3 (out of 10)
• Opioid use fell from 61% → 24%
• Younger age was the strongest predictor of better outcome
• Disease duration and etiology (genetic vs other) did NOT affect response

• Physical QoL improved by ≥10 points in 58% of patients
• Mental QoL improved by ≥10 points in 35%

• Mean HbA1c = 7% at 1 year
• 20% fully insulin independent at 1 year (adult-dominated cohort)
• Pediatric-specific registries show much better rates - see below

Pediatric-Specific Outcomes

• Greater insulin sensitivity per kg body weight
• Higher relative islet yields from their less fibrotic pancreases
• Better cellular recovery from major surgery

• All 17 children discontinued narcotic use within a median of 68 days post-surgery
• 100% off opioids by 1 year
• 82% had at least partial insulin independence
• 64% were completely insulin independent at last follow-up

The Islet Dose - Why It Matters

The Procedure Step by Step

1. Total pancreatectomy + splenectomy (often) + duodenectomy
2. Pancreas sent immediately to the islet processing laboratory (same hospital)
3. Enzymatic digestion dissolves the pancreatic tissue, freeing islet clusters
4. Islets purified by density gradient centrifugation
5. Quality control: islet count, viability, sterility checks
6. Islet suspension infused into portal vein via interventional radiology
7. Islets lodge in liver sinusoids → engraft → resume insulin secretion within days-weeks

Risks and What Patients/Families Must Know

• Reoperation rate: ~16% (most commonly for bleeding)
• In-hospital mortality: ~1.2% at major centers
• Post-operative leak, infection, ileus

• Even with perfect islet engraftment, some patients will eventually require insulin as islet mass slowly declines over years
• HbA1c management is complex - neither the high-glucose risk of type 1 DM nor severe hypoglycemia, but requires monitoring
• Portal vein thrombosis is a rare but serious complication of the islet infusion

• Lifelong pancreatic enzyme replacement (PERT) is mandatory - no pancreas means no digestive enzymes
• Fat-soluble vitamin monitoring (A, D, E, K)
• Splenectomy (if performed) requires lifelong pneumococcal, meningococcal, and Hib vaccination

Where TP-IAT Is Available

• University of Minnesota (largest program worldwide)
• Cincinnati Children's Hospital Medical Center
• University of Leicester (UK)
• Children's Hospital at VCU (Virginia Commonwealth - reported a 10-year-old pain-free post-TP-IAT in April 2026)
• South Australia - published 10-year pediatric experience (Radisic et al., 2026 [PMID: 41555675])

Is TP-IAT Right for Yagay Now?